



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,531	12/22/2003	Timothy P. Mate	341148004US3	7678
69414	7590	06/30/2009	EXAMINER	
CALYPSO MEDICAL / PERKINS COIE, LLP			ROZANSKI, MICHAEL T	
P.O. BOX 1247				
SEATTLE, WA 98111-1247			ART UNIT	PAPER NUMBER
			3768	
			MAIL DATE	DELIVERY MODE
			06/30/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/743,531	MATE ET AL.	
	Examiner	Art Unit	
	MICHAEL T. ROZANSKI	3768	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 01 June 2009.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 144-150 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 144-150 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>6/1/09</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Claim Objections

Claims 144-150 are objected to because of the following informalities:

Amendments refer to sensors (plural), while subsequent mention of same elements is referred to as sensor (singular). Appropriate correction is required.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 144-150 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vilsmeier et al (US 6,611,700) in view of Krag (US PUB 2003/0192557 with priority to 5/14/98).

Vilsmeier et al disclose a method and apparatus for positioning a patient 1 lying on a bench 9 for radiation treatment. The patient is positioned such that the isocenter 3 is located in the center of the tumor 2 to be irradiated. A glass fiber cable 6, which serves as a position sensor, is attached to a controller 8 so that the position and directional vector of the outgoing glass fiber 6 is clearly defined by a connecting point serving as a fiducial point to permit obtaining information regarding the location of the glass fiber 6 as a whole using this fiducial point.

The other end of the cable 6 is implanted in the patient body 1 and fixed in the site of the tumor 2, the end point 4 of the cable 6 not being located on the tumor. By using the positional information of the cable 6 established by the controller 8, the absolute momentary position of the tumor 2 can be detected by determining the position of the end point 4 and/or of a further optional point 5 on the cable. The controller detects the three-dimensional position of individual points 4, 5 and is then able to determine whether the tumor 2 is in the permitted site circumscribing the isocenter and to suitably control the patient bench 9 to position the tumor 2 and/or the radiation source accordingly. The radiation source turns OFF when the tumor 2 moves out of the isocenter 3 and back ON when tumor 2 is in the isocenter 3 (col 4, line 56-col 5, line 26). The controller 8 is a device that loads and executes computer program code and, therefore, is a computer including computer operable instructions. In addition, the controller 8 repeatedly receives positional information of the individual points 4, 5, determines a location of the marker relative to a frame of reference defined by positional information of the glass fiber cable 6, and computes a displacement between the location of the marker and a desired location of the marker wherein the target is located at a desired situs in the reference frame when the marker is at the desired location for the marker (see col 5, lines 17-26). This also indicates that the bench 9 is moved according to the actual location of the target if a displacement between the actual location of the target and a desired location for the target is beyond an acceptable range.

Vilsmeier et al disclose that the position sensor is a glass fiber cable, thereby not transmitting information wirelessly. However, Vilsmeier et al also states that in principle, any sensor may be used as the position sensor enabling the three-dimensional location (col 2, lines 16-19). Furthermore, Vilsmeier et al teach of a unit 8 that receives the position information, rather than a plurality of sensors in a fixed and known geometry relative to each other.

Krag teach of tracking a marker via a plurality of sensors in a fixed and known geometry relative to each other. Krag discloses a configuration in that the position of an implantable marker 1100 is wirelessly sensed by a plurality of sensors 1210 in a fixed and known geometry [0150]. The marker is activated by transmitter 1220, which emits an excitation energy that causes the implantable marker to emit a response energy that is detected by sensor array 1204 (see Figures 21 and 22).

It would have been obvious to one with ordinary skill in the art at the time the invention was made to modify Vilsmeier et al, to replace the marker tracking system with one including a plurality of fixed sensors as taught by Krag, because such is merely a substitution of one tracking system with another. Specifically, the skilled artisan would understand that the modification includes placing the marking element of Krag at the site of the tumor at which the glass fiber cable 6 of Vilsmeier is fixedly attached. Such a modification would not render Vilsmeier inoperable because it involves a substitution of parts (i.e. the mechanism by which the marker at the tumor site is tracked) and does not change the principle of operation.

In regard to claims 148-150, Vilsmeier et al disclose that the controller 8 receives information regarding the absolute momentary position of the tumor, but do not teach that this information is stored or sent to a memory. However, it is well established in the art that many computers and controllers have data storage capabilities. Therefore, it would have been obvious to one with ordinary skill in the art at the time the invention was made to modify Vilsmeier et al to include a memory with the controller in order to store information regarding the desired target site to help move the patient for initial alignments with the beam isocenter.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 144-150 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-55 and

82-84 of copending Application No. 09/877,498 in view of Vilsmeier et al (US 6,611,700). '498 includes substantially all the limitations of the pending claims including the wireless implantable marker, the plurality of sensors configured to measure the marker signal, and a computer to receive the measured signals to determine the location of a selected target within a body for radiation treatment. However, '498 does not include several limitations such as the movable patient support. Vilsmeier et al teach positioning a body on a support in view of a sensed position of a marker at the target site. It would have been obvious to modify '498 to include the support features in order to facilitate radiation treatment delivery.

This is a provisional obviousness-type double patenting rejection.

Response to Arguments

Applicant's arguments, see arguments, filed 4/30/09, with respect to Dumoulin have been fully considered and are persuasive. The rejection of claims 144-150 over Vilsmeier in view of Dumoulin has been withdrawn.

Applicant has not overcome the rejection over Vilsmeier and Krag, as Applicant has deferred overcoming the Krag reference by removing as 103(a)/(c) and has not addressed the details of the combination of Vilsmeier and Krag. Further, Applicant has not addressed the claim objections. In addition, the terminal disclaimer has not been approved because there is no power of attorney/more than 10 practitioners listed on the power of attorney (see rule 37 CFR 1.32(c)(3)). Therefore, this action is made Final.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL T. ROZANSKI whose telephone number is (571)272-1648. The examiner can normally be reached on Monday - Friday, 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Eric F Winakur/
Primary Examiner, Art Unit 3768

MR